Algorhythm Holdings Reports First Quarter 2025 Financial Results
Fort Lauderdale, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. ('Algorhythm') (NASDAQ: RIME) – an AI technology and consumer electronics holding company, announced today its results of operations for the three-month period ended March 31, 2025.
Q1 2025 Financial Highlights
Algorhythm reported revenue of $2.0 million for the three months ended March 31, 2025 compared to $2.4 million for the three months ended March 31, 2024.
Gross profit margin increased by 4.4% to 25.1% from 20.7% compared to the same period of the prior year. Gross profit was $0.5 million for the three months ended March 31, 2025.
Loss from operations increased $0.5 million to $2.8 million for the three months ended March 31, 2025, compared to $2.3 million for the three months ended March 31, 2024.
Net loss increased $6.8 million to $9.2 million for the three months ended March 31, 2025, compared to $2.4 million for the three months ended March 31, 2024.
Adjusted net loss, a non-GAAP measure, was $3.2 million for the three months ended March 31, 2025, compared to $2.4 million for the three months ended March 31, 2024.
Inventory was reduced by 14% during the three months ended March 31, 2025, from $2.2 million as of December 31, 2024 to $1.9 million as of March 31, 2025.
The Company had cash on hand to $3.3 million as of March 31, 2025.
A reconciliation of adjusted net loss on a GAAP and non-GAAP basis is included in the table below entitled 'Reconciliation of GAAP to non-GAAP Financial Measures'.
2025 Business Highlights
'2025 is off to an incredible start, highlighted by our recent acquisition of SMCB Solutions Private Ltd. ('SemiCab India'), which operates SemiCab's AI enabled, cloud-based Collaborative Transportation Platform in the Indian market,' stated Gary Atkinson, Chief Executive Officer of Algorhythm. 'SemiCab India is currently operating at an annualized revenue run rate of $4.6 million with projected volume from its national and multinational customers expected to double that run rate by the end of the year. In addition, SemiCab India recently expanded its active fleet to 140 trucks and has access to an additional 450 trucks which, in the event actual growth exceeds projected growth, provides it with the capacity to quadruple its annualized revenue run rate from $4.6 million to over $23 million during the second half of 2025. Algorhythm plans to develop its pipeline of pending contracts with new full truckload (FTL) carriers to grow its fleet to over 1,000 vehicles by the end of 2025 to keep pace with demand.'
'I am highly optimistic at the Company's outlook for the back half of 2025 and beyond,' continued Mr. Atkinson. 'I believe our strategic pivot into AI logistics services with SemiCab will prove to be the correct decision, particularly during this period of extreme economic volatility. We have already seen a seismic move of manufacturing coming into India as a result of tariffs. We foresee this will create opportunities to solve logistics problems and force more optimization throughout the transportation industry. We are committed to continue to invest into the growth of our SemiCab business to take advantage of these opportunities.'
Q1 2025 Financial Summary
Algorhythm generated revenue of $2.0 million for the three months ended March 31, 2025 compared to $2.4 million for the same period last year. 'Our decrease in revenue was due primarily to lower sales within our karaoke business,' commented Alex Andre, Chief Financial Officer of Algorhythm. 'Sales of our karaoke products will likely continue to decrease due to the negative impact on our business of recently implemented tariffs, however, we expect this to be offset by an increase in revenue that we expect to generate from our SemiCab business. Our recent acquisition of SemiCab India will positively impact our revenue for the remainder of 2025.'
The Company reported a net loss for the three-month period ended March 31, 2025 of $9.2 million, compared to a net loss of $2.4 million in the same period of the prior year. The increase was due primarily to a substantial increase in non-cash expenses of $6.4 million for the change in fair value of warrants that the Company issued in December 2024 as part of a public offering. Excluding non-cash expenses, Algorhythm's adjusted net loss was $3.2 million for the quarter.
'The warrants that we issued in December 2024 were subject to certain contingencies that resulted in us recording a warrant liability of $16.6 million on our balance sheet at December 31, 2024 and a loss of $6.4 million on our income statement for Q1 2025,' stated Mr. Andre. 'All of these contingencies were satisfied or became moot during Q1 2025. As a result, we reclassified the entire warrant liability to equity on our balance sheet at March 31, 2025. We will not incur any future non-cash charges associated with changes in the fair value of these warrants.'
Non-GAAP Financial Measures
The Company prepares it's consolidated financial statements in accordance with United States generally accepted accounting principles ('GAAP'). In addition to disclosing financial information prepared in accordance with GAAP, this release also includes non-GAAP operating income, non-GAAP net income and non-GAAP net income per share data for the periods presented. Management uses non-GAAP financial measures internally for financial and operational decision-making and as a means to evaluate period-to-period comparisons. The Company's management believes that these non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the Company's core business operations, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making.
These non-GAAP financial measures are not recognized measures for financial statement presentation under U.S. GAAP and do not have standardized meanings. Accordingly, they may be different from similar non-GAAP financial measures presented by other companies. These non-GAAP financial measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP financial measures. Investors should consider these non-GAAP financial measures as a supplement to, and not as a substitute for, corresponding financial measures calculated in accordance with GAAP.
For the purposes of this press release, the following non-GAAP financial measures have the following meanings:
'Adjusted net loss' means net loss plus depreciation and amortization, reduction in SMCB loan in exchange for services, provision for estimated cost of returns, change in fair value of warrant liability, provision for inventory obsolescence, credit losses, reserve for sales returns, and stock-based compensation.
For further information, please refer to the Company's Annual Report on Form 10-K filed with the SEC on April 15, 2025 and available online at www.sec.gov.
For a reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, please see the table below entitled 'Reconciliation of GAAP to Non-GAAP Financial Measures'.
Conference Call Details:
Date: Friday, May 16, 2025 Time: 10:00 a.m. EDT Dial-in number: 888-999-3182 Conference ID: RIME
An audio rebroadcast of the call will be available later in the day at:
https://ir.algoholdings.com
About Algorhythm Holdings
Algorhythm Holdings, Inc. is an AI technology and consumer electronics holding company with two primary business units – SemiCab and Singing Machine.
SemiCab is an emerging leader in the global logistics and distribution industry. Since 2020, SemiCab has enabled major retailers, brands and transportation providers to address these common supply-chain problems globally. Its AI-enabled, cloud-based Collaborative Transportation Platform achieves the scalability required to predict and optimize millions of loads and hundreds of thousands of trucks. SemiCab uses real-time data from API-based load tendering and pre-built integrations with TMS and ELD partners to orchestrate collaboration across manufacturers, retailers, distributors, and their carriers. SemiCab uses AI/ML predictions and advanced predictive optimization models to enable fully loaded round trips. With SemiCab's AI platform, shippers pay less and carriers make more without having to change a thing.
For additional information, please go to: http://www.semicab.com
Singing Machine is the worldwide leader in consumer karaoke products. Based in Fort Lauderdale, Florida, and founded over forty years ago, it designs and distributes the industry's widest assortment of at-home and in-car karaoke entertainment products. Its product portfolio is marketed under both proprietary brands and popular licenses, including Carpool Karaoke and Sesame Street. Singing Machine products incorporate the latest technology and provide access to over 100,000 songs for streaming through its mobile app and select Wi-Fi-capable products and is also developing the world's first globally available, fully integrated in-car karaoke system. Its products are sold in over 25,000 locations worldwide, including Amazon, Costco, Sam's Club, Target, and Walmart.
For additional information, please go to www.singingmachine.com.
Investor Relations Contact:investors@algoholdings.comwww.algoholdings.com
Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described from time to time in Algorhythm's reports to the SEC, including, without limitation Algorhythm's Annual Report on Form 10-K for the year ended December 31, 2024. You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this press release to conform our statements to actual results or changed expectations, or as a result of new information, future events or otherwise.
Algorhythm Holdings, Inc. and Subsidiaries
Consolidated Balance Sheets (Unaudited)
March 31, 2025
December 31, 2024
Assets
Current Assets
Cash
$
3,296,000
$
7,550,000
Accounts receivable, net of allowances of $396,000 and $275,000, respectively
1,385,000
4,373,000
Accounts receivable, related party
357,000
212,000
Note receivable, related party
1,201,000
701,000
Inventory
1,895,000
2,186,000
Returns asset
751,000
1,621,000
Prepaid expenses and other current assets
126,000
120,000
Total Current Assets
9,011,000
16,763,000
Property and equipment, net
253,000
284,000
Other non-current assets
81,000
124,000
Intangible assets, net
330,000
345,000
Goodwill
786,000
786,000
Total Assets
$
10,461,000
$
18,302,000
Liabilities and Shareholders' Equity
Current Liabilities
Accounts payable
$
1,301,000
$
3,808,000
Accrued expenses
2,414,000
4,224,000
Refund due to customer
630,000
38,000
Reserve for sales returns
1,742,000
3,355,000
Warrant liability
-
16,603,000
Current portion of notes payable to related parties
551,000
265,000
Other current liabilities
97,000
145,000
Total Current Liabilities
6,735,000
28,438,000
Notes payable to related parties, net of current portion
385,000
385,000
Total Liabilities
7,120,000
28,823,000
Commitments and Contingencies
Shareholders' Equity (Deficit)
Preferred stock, $1.00 par value; 1,000,000 shares authorized; no shares
issued and outstanding at March 31, 2025 and December 31, 2024
-
-
Common stock, $0.01 par value; 800,000,000 and 100,000,000 shares authorized;
2,394,829 and 470,825 shares issued and outstanding at March 31, 2025 and
December 31, 2024
24,000
5,000
Additional paid-in capital
63,577,000
39,682,000
Accumulated deficit
(58,363,000
)
(49,172,000
)
Non-controlling interest
(1,139,000
)
(1,036,000
)
Treasury stock, 10,990 and -0- shares reserved at March 31, 2025 and 2024
(758,000
)
-
Total Algorhythm Holdings Shareholders' Equity (Deficit)
3,341,000
(10,521,000
)
Total Liabilities and Shareholders' Equity (Deficit)
$
10,461,000
$
18,302,000
Algorhythm Holdings, Inc. and Subsidiaries
Consolidated Statements of Operations (Unaudited)
Three Months Ended March 31,
2025
2024
Net Sales
$
1,993,000
$
2,426,000
Cost of Goods Sold
1,493,000
1,924,000
Gross Profit
500,000
502,000
Operating Expenses
Selling expenses
764,000
630,000
General and administrative expenses
2,546,000
2,159,000
Total Operating Expenses
3,310,000
2,789,000
Loss from Operations
(2,810,000
)
(2,287,000
)
Other Expenses
Change in fair value of warrant liability
(6,468,000
)
-
Interest expense
(16,000
)
(28,000
)
Total Other Expenses
(6,484,000
)
(28,000
)
Loss Before Income Tax Benefit
(9,294,000
)
(2,315,000
)
Income Tax Provision
-
(52,000
)
Net Loss
(9,294,000
)
(2,367,000
)
Net loss attributable to non-controlling interest
103,000
-
Net Loss Available to Common Stockholders
$
(9,191,000
)
$
(2,367,000
)
Loss per common share
Basic and diluted
$
(4.66
)
$
(73.76
)
Weighted Average Common and Common
Equivalent Shares:
Basic and diluted
1,972,869
32,090
Algorhythm Holdings, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)
Table 1: Adjusted Net Loss
For the Three Months Ended March 31,
2025
2024
Net loss (as reported)
$
(9,294,000
)
$
(2,367,000
)
Depreciation and amortization
91,000
136,000
Reduction in SMCB loan in exchange for services
172,000
-
Provision for estimated cost of returns
870,000
658,000
Change in fair value of warrant liability
6,468,000
-
Provision for inventory obsolescence
4,000
-
Credit losses
3,000
101,000
Reserve for sales returns
(1,614,000
)
(971,000
)
Stock based compensation
85,000
19,000
Adjusted net loss
$
(3,215,000
)
$
(2,424,000
)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
17 minutes ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. ('Zenas' or the 'Company') (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zenas' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zenas BioPharma class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Yahoo
34 minutes ago
- Yahoo
1 Stock Down 34% This Year to Buy and Hold
Investors are withdrawing their money from stocks like Viking Therapeutics due to the current uncertainty. However, the biotech has a duo of mid-stage candidates that look incredibly promising. Though it carries above-average risk, Viking has significant upside potential. 10 stocks we like better than Viking Therapeutics › Shares of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, are down by 34% this year. This poor performance may suggest that recent company-specific developments have rendered the stock less attractive or that it is being affected by broader market issues. The latter is true, at least to some extent, but Viking Therapeutics' thesis has not changed significantly this year. The drugmaker remains attractive compared to most of its similarly sized peers. Here is why. Viking Therapeutics is a clinical-stage biotech. That means the company has no product on the market, generates no revenue, and is consistently unprofitable. Investors aren't too keen on buying shares of companies that fit this profile when broader equities are experiencing significant volatility due to potential macroeconomic issues. In fairness, that makes sense. Clinical-stage biotechs carry above-average risk. Their products may never see the light of day outside the clinic, and even when they do, many do not generate substantial revenue. However, Viking Therapeutics is a bit different. The company is developing medicines across several areas with high unmet needs. First, there is the drugmaker's work in the weight management space. The anti-obesity drug market has experienced significant growth in recent years. Yet, analysts continue to predict that the best is yet to come. Viking Therapeutics' leading candidate in this area, VK2735, is a dual GLP-1/GIP agonist. The only approved medicine of this kind on the market is Eli Lilly's Zepbound, an undisputed leader. Being in the same class as Zepbound doesn't guarantee VK2735's success, but it's still worth pointing out that a similar mechanism of action that led to Zepbound's breakthrough and efficacy could also prove successful for Viking Therapeutics' crown jewel. And more importantly, the investigational medicine has produced better results than almost any other mid-stage candidate in weight management, outside of those being developed by Eli Lilly and Novo Nordisk. That's impressive for a mid-cap biotech, considering significantly larger drugmakers with far more resources are trying to dominate this market. Viking Therapeutics' other mid-stage program, VK2809, performed well in patients with metabolic dysfunction-associated steatohepatitis (MASH), a disease with obesity as one of the main risk factors and whose prevalence is on the rise. However, the U.S. Food and Drug Administration approved just the first MASH medicine last year, although that will likely change soon. The point, though, is that VK2809 could join a relatively young market in a few years and generate massive sales down the road. These two candidates set Viking Therapeutics apart from other clinical-stage biotech companies. It's also worth noting that Viking Therapeutics recently signed a multiyear manufacturing agreement with privately held CordenPharma for VK2735. Per the terms of the deal, CordenPharma will manufacture more than a billion oral formulations of the medicine annually, as well as over 100 million autoinjectors and another 100 million syringes per year. Viking Therapeutics will make payments to CordenPharma, totaling $150 million through 2028. This deal highlights that Viking Therapeutics is already planning some post-commercial activity for its leading candidate. That's a great sign for investors. Viking Therapeutics is developing other candidates, including another weight management product that is still in preclinical studies. Following a similar blueprint, this product is a dual agonist that mimics the action of not just one but two gut hormones: amylin, which helps regulate blood sugar, and calcitonin, which regulates calcium levels. There is slow progress on that front, but Viking Therapeutics' commitment to innovation is impressive for such a small biotech. Now, Viking Therapeutics' most advanced programs could fail in phase 3 studies. If that happens, especially with VK2735, the stock price is likely to plummet. That's a significant risk to consider. That's why the stock is probably not suitable for risk-averse investors. However, those who are comfortable with volatility should strongly consider initiating a small position in the stock. If the business goes under, which isn't that rare for smaller biotech companies, your losses will be relatively small so long as the company makes a tiny portion of your overall portfolio. But there is significant upside potential that those who invest in Viking Therapeutics today could enjoy over the long run. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Stock Down 34% This Year to Buy and Hold was originally published by The Motley Fool

Associated Press
34 minutes ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Red Cat Holdings
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Red Cat To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Red Cat between March 18, 2022 and January 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Red Cat Holdings, Inc. ('Red Cat' or the 'Company') (NASDAQ: RCAT) and reminds investors of the July 21, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Salt Lake City Facility's production capacity, and Defendants' progress in developing the same, was overstated; (2) the overall value of the SRR Contract was overstated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. In March 2022, Red Cat announced that Teal had been selected by the U.S. Department of Defense's Defense Innovation Unit and the U.S. Army to compete in Tranche 2 of the U.S. Army's Short Range Reconnaissance Program of Record (the 'SRR Program'). The SRR Program is a U.S. Army initiative to provide a small, rucksack-portable sUAS to U.S. Army platoons. At all relevant times, Defendants suggested or otherwise asserted that the SRR Program's Tranche 2 contract (the 'SRR Contract') was worth potentially hundreds of millions to over a billion dollars in contract revenues. In March 2023, Company management confirmed that "[t]he Salt Lake City factory is complete and ready to go' and "[w]e now have the capacity to produce thousands of drones per month.' The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Salt Lake City Facility's production capacity, and Defendants' progress in developing the same, was overstated; (ii) the overall value of the SRR Contract was overstated; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times. On July 27, 2023, Red Cat hosted a conference call with investors and analysts to discuss its financial and operating results for its fiscal year 2023. During the call, Defendants revealed that the Salt Lake City Facility could only currently produce 100 drones per month, and that the facility was still being built, refined, and expanded. Red Cat filed an annual report on Form 10-K with the U.S. Securities and Exchange Commission the same day, which likewise reported that construction of the facility was only 'substantially completed' and potentially could reach a production capacity of one thousand drones per month over the next 2 to 3 years, but only with additional capital investments and manufacturing efficiencies realized. Following these disclosures, Red Cat's stock price fell $0.10 per share, or 8.93%, to close at $1.02 per share on July 28, 2023. On September 23, 2024, Red Cat issued a press release announcing its financial and operating results for the first quarter of its fiscal year 2025. Among other results, the Company reported losses per share of $0.17, missing consensus estimates by $0.09, and revenue of $2.8 million, missing consensus estimates by $1.07 million. On a subsequent conference call that Red Cat hosted with investors and analysts the same day to discuss these results, Company management disclosed that Red Cat had spent 'the past four months . . . retooling [the Salt Lake City Facility] and preparing for high volume production[,]' while admitting that a 'pause in manufacturing of Teal 2 and building our Army prototypes impacted Teal 2 sales' because, inter alia, Red Cat 'couldn't produce and sell Teal 2 units[] while retooling [its] factory.' On this news, Red Cat's stock price fell $0.80 per share, or 25.32%, over the following two trading sessions, to close at $2.36 per share on September 25, 2024. On November 19, 2024, Red Cat issued a press release announcing that it had won the SRR Contract. On a subsequent conference call that Red Cat hosted with investors and analysts the same day to discuss the contract win, Defendants continued to assert that the SRR Contract was worth potentially hundreds of millions of dollars, while expressing their confidence that Red Cat could realize up to $50 million to $79.5 million in revenue from the SRR Contract during it fiscal year 2025 alone. Then, on January 16, 2025, Kerrisdale Capital ('Kerrisdale') published a report (the 'Kerrisdale Report') alleging, inter alia, that Defendants had overstated the value of the SRR Contract, which Kerrisdale found was only worth approximately $20 million to $25 million based on U.S. Army budget documents. The Kerrisdale Report also alleged that Defendants had been misleading investors about the Salt Lake City Facility's production capacity for years, while also raising concerns about the timing of executive departures and insider transactions that took place shortly after Red Cat announced it had won the SRR Contract. On this news, Red Cat's stock price fell $2.35 per share, or 21.54%, over the following two trading sessions, to close at $8.56 per share on January 17, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Red Cat's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Red Cat class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit